Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-250 vs ANDROID 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.
Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.
Intravascular use for computed tomography (CT) of the head and body,Intrathecal use for lumbar, thoracic, and cervical myelography,Coronary arteriography and ventriculography,Peripheral arteriography,Excretory urography,Visceral angiography
Hypogonadism in males (primary and secondary),Delayed puberty in males,Metastatic breast cancer in women (as palliative therapy)
Intravenous administration of 50-150 m L (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 m L (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.
Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.
Terminal elimination half-life: 1.5-2 hours (normal renal function); clinically, half-life prolonged in renal impairment
Terminal elimination half-life: 10–100 minutes (testosterone); clinical context: rapid clearance necessitates frequent dosing or use of esters for sustained effect
Iopamidol is not metabolized. It is excreted unchanged by glomerular filtration, primarily via the kidneys. In patients with normal renal function, 90% or more of the administered dose is eliminated in the urine within 24 hours.
Primarily hepatic via reduction and oxidation; metabolites include androsterone and etiocholanolone; excreted in urine.
Primarily renal: 90-95% unchanged in urine within 24 hours; biliary/fecal: <5%
Renal: 90% (as glucuronide and sulfate conjugates, 5–10% unchanged); fecal/biliary: 10%
<5% bound; primarily to albumin
97–99% (sex hormone-binding globulin and albumin)
0.2-0.3 L/kg; reflects distribution in extracellular fluid (does not cross intact blood-brain barrier)
0.3–0.6 L/kg; indicates distribution into lean muscle and sex organs
Intravascular: 100%; oral: negligible (<1%)
Oral: <5% (methyltestosterone: ~20–25% due to 17α-alkylation); IM: 100%
e GFR <30 m L/min/1.73m²: avoid use or use minimal dose with adequate hydration; e GFR 30-59: consider lowest effective dose and ensure hydration; no specific dose reduction for e GFR ≥60.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose or increasing interval; monitor for fluid retention and hypertension.
No specific Child-Pugh based dose modifications; use with caution in severe hepatic impairment due to potential contrast-induced nephropathy risk.
Contraindicated in Child-Pugh class B or C cirrhosis. For mild hepatic impairment (Child-Pugh A), start with lower dose (e.g., 12.5 mg every 2 weeks) and titrate based on response and liver function.
Children: 1-2 m L/kg (250-500 mg iodine/kg) intravenously for CT, not to exceed adult dose; adjust for body weight and procedure.
Not recommended for use in pediatric patients (safety and efficacy not established). For male adolescents with hypogonadism, individualize: start at 12.5 mg every 2 weeks and adjust based on testosterone levels and growth.
Elderly patients: use lowest effective dose; ensure adequate hydration; monitor renal function closely due to age-related decline and increased risk of nephropathy.
Start with lower initial dose (e.g., 12.5 mg every 2 weeks); monitor prostate-specific antigen (PSA) and hematocrit frequently. Avoid in patients with prostate cancer or untreated sleep apnea.
Intrathecal administration may result in neurotoxicity including seizures, meningitis, and arachnoiditis. Inadvertent intravascular injection during intrathecal administration may cause serious adverse reactions.
WARNING: Androgens are contraindicated in pregnancy due to masculinization of female fetus. Hepatotoxicity, including peliosis hepatis and hepatic neoplasms, has been reported with prolonged use.
Do not use for myelography if procedures are contraindicated,Risk of serious adverse reactions in patients with impaired renal function, including acute renal failure,Risk of cardiorespiratory arrest, anaphylactic shock, and other severe allergic reactions,Potential for thyroid storm in patients with hyperthyroidism,Caution in patients with pheochromocytoma, sickle cell disease, and multiple myeloma
Use with caution in patients with hepatic, renal, or cardiovascular disease; may cause gynecomastia, edema, hypercalcemia, and polycythemia; monitor liver function, lipid profile, and hematocrit periodically; may accelerate bone maturation in children; risk of prostate hypertrophy and urethral obstruction.
History of severe allergic reaction to iopamidol or any component of the formulation,Intrathecal administration in patients with thrombophlebitis, infection, or malignancy at the injection site,Severe renal impairment (anuria, oliguria) unless the benefits outweigh the risks,Patients with a history of grand mal seizures, or those on drugs that lower seizure threshold, for intrathecal use
Known or suspected prostate cancer; male breast cancer; pregnancy; lactation; hypersensitivity to methyltestosterone; severe hepatic impairment.
No known food interactions. However, ensure adequate hydration before and after the procedure. Avoid alcohol 24 hours prior as it may increase risk of dehydration.
Take with food containing fat (e.g., avocado, nuts, olive oil) to enhance absorption. Avoid grapefruit juice as it may increase testosterone levels via CYP3A4 inhibition. Limit alcohol due to potential liver effects.
ISOVUE-250 (iopamidol) is an iodinated contrast agent. In pregnant women, exposure to ionizing radiation from procedures involving iodinated contrast should be minimized. Iodinated contrast agents cross the placenta and may produce transient neonatal hypothyroidism if used in the third trimester. However, data from clinical studies are insufficient to determine a definitive teratogenic risk. First trimester exposure has not been associated with major congenital malformations, but caution is warranted due to potential fetal hypothyroidism with prolonged use near term.
Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure occurs before 12 weeks gestation. Second and third trimesters: Continued risk of female pseudohermaphroditism, and potential for masculinization of female external genitalia. Androgens can cross the placenta and may also cause skeletal abnormalities and growth retardation. Pregnancy category X.
Limited data suggest that iopamidol is excreted into human breast milk in very small amounts. The milk-to-plasma (M/P) ratio is not specifically reported for iopamidol, but for similar iodinated contrast agents, the M/P ratio is low (<0.2). The amount of iodine transferred to the infant is negligible and unlikely to cause adverse effects. However, the American College of Radiology and other guidelines recommend that breastfeeding may be continued without interruption after receiving iodinated contrast, although some advise discarding milk for 12-24 hours if the mother is concerned.
Methyltestosterone is excreted into breast milk; M/P ratio not established. May cause virilization in female infants and premature sexual development in male infants. Androgens can suppress lactation. Use during breastfeeding is contraindicated.
Pregnancy does not require dose adjustments for ISOVUE-250. The dose should be based on the diagnostic procedure and patient weight. However, because of potential fetal hypothyroidism risk from free iodide, alternative imaging modalities without iodinated contrast should be considered if possible, especially in the third trimester.
Android 25 is contraindicated in pregnancy, so no dosing adjustments are applicable. If used inadvertently, discontinue immediately. No pharmacokinetic data to guide dose changes; avoid use entirely.
ISOVUE-250 (iopamidol 51%) is a nonionic, low-osmolality iodinated contrast medium used for angiography, urography, and CT enhancement. In patients with renal impairment (e GFR <30 m L/min), consider N-acetylcysteine prophylaxis and hydration to reduce risk of contrast-induced nephropathy. Monitor for delayed hypersensitivity reactions, which can occur up to 7 days post-administration. Use caution in patients with pheochromocytoma; pre-treat with alpha-blockers. Shellfish allergy is not a contraindication; true iodine allergy is rare. For intrathecal use, avoid concurrent neurotoxic drugs and ensure patient hydration.
Android 25 (testosterone undecanoate) requires absorption via lymphatic system; administer with fat-containing meal. Monitor serum testosterone levels 3-5 hours post-dose. Avoid in patients with breast cancer or known or suspected prostate cancer. Risk of polycythemia; check hematocrit before and during therapy.
Inform your doctor if you have kidney disease, diabetes, or are taking metformin; metformin may need to be stopped temporarily.,Tell your doctor about all allergies, especially to medications or iodine.,You may feel warmth, flushing, or a metallic taste when the contrast is injected; this is normal.,Drink plenty of water before and after the procedure to help flush the contrast from your body.,Report any symptoms like hives, itching, difficulty breathing, or swelling of the face/mouth immediately.,If you are pregnant or breastfeeding, discuss potential risks with your doctor.
Take capsules with meals, especially those containing fat, to improve absorption.,Do not chew or crush capsules; swallow whole.,Report signs of deep vein thrombosis (leg swelling, pain) or pulmonary embolism (sudden dyspnea, chest pain).,Women of reproductive potential should avoid pregnancy; use effective contraception.,Keep out of reach of children; testosterone can cause serious harm if accidentally ingested.,Regular blood tests (testosterone, hematocrit, PSA, lipid profile) are required.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-250 vs ANDROID 25, answered by our medical review team.
ISOVUE-250 is a Contrast Media that works by Iopamidol is a nonionic, water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby providing contrast enhancement in imaging studies. Its mechanism of action is physical rather than pharmacological, as it does not have inherent biological activity.. ANDROID 25 is a Androgen that works by Android 25 contains methyltestosterone, a synthetic androgen that binds to androgen receptors, promoting protein synthesis and anabolic effects. It also inhibits gonadotropin secretion from the pituitary, reducing endogenous testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-250 and ANDROID 25 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-250 is: Intravenous administration of 50-150 m L (12-37 g iodine) for CT imaging; intra-arterial administration of 10-80 m L (2.5-20 g iodine) for angiography; dose depends on procedure and patient weight.. The standard adult dose of ANDROID 25 is: Testosterone 25 mg subcutaneously or intramuscularly every 2 to 4 weeks. Alternatively, 125 mg intramuscularly every 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-250 and ANDROID 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-250 is classified as Category C. ISOVUE-250 (iopamidol) is an iodinated contrast agent. In pregnant women, exposure to ionizing radiation from procedures involving iodinated contrast should be minimized. Iodinated. ANDROID 25 is classified as Category C. Android 25 (methyltestosterone) is an androgen. First trimester: Virilization of female fetus, including clitoromegaly, labial fusion, urogenital sinus abnormalities if exposure oc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.